The Directory of Open Access Journals
DOAJ Logotype
Open
Global
Trusted
Main actions
Support
Institutions and libraries
Publishers
Institutional and library supporters
Apply
Application form
Guide to applying
The DOAJ Seal
Transparency & best practice
Publisher information
Licensing & copyright
Search
Menu
Secondary actions
Search
Journals
Articles
Documentation
API
OAI-PMH
Widgets
Public data dump
OpenURL
XML
Metadata help
Preservation
About
About DOAJ
DOAJ at 20
DOAJ team
Ambassadors
Advisory Board & Council
Volunteers
News
Support
Institutions and libraries
Publishers
Institutional and library supporters
Apply
Application form
Guide to applying
The DOAJ Seal
Transparency & best practice
Publisher information
Licensing & copyright
Login
Login
Quick search
Close
×
Journals
Articles
Search by keywords:
In the field:
In all fields
Title
ISSN
Subject
Publisher
Country of publisher
Search
Frontiers in Oncology
(Feb 2023)
Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?
Jennifer Edelmann,
Jitka Malcikova,
Jitka Malcikova,
John C. Riches,
John C. Riches
Affiliations
Jennifer Edelmann
ClinSciNet - The Clinician Scientist Network, Münsingen, Germany
Jitka Malcikova
Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czechia
Jitka Malcikova
Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czechia
John C. Riches
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
John C. Riches
Department of Haemato-Oncology, Barts Health NHS Trust, St. Bartholomew’s Hospital, London, United Kingdom
DOI
https://doi.org/10.3389/fonc.2023.1106579
Journal volume & issue
Vol. 13
Abstract
Read online
No abstracts available.
Keywords
chronic lymphocytic leukemia (CLL)
high-risk
TP53
definition
BTK - Bruton’s tyrosine kinase
BCL2 (B-cell lymphoma 2)
WeChat QR code
Close